- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bronchiectasis
- Interventions
- 280 mg Arikayce™, Matching Placebo for Cohort 1, 560 mg Arikayce™, Matching Placebo for Cohort 2
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Philadelphia, Pennsylvania
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- ALIS, Azithromycin, Ethambutol, ELC
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Fresno, California • San Diego, California + 24 more
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- Liposomal amikacin for inhalation (LAI), placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Stanford, California • Denver, Colorado + 15 more